71% of retail investors in the UAE hold stocks in companies engaged with AI
markets1 hour ago
Dr. Mohamed Salim Al Olama, Under-Secretary of the Ministry of Health and Prevention, MoHAP, has revealed the registration of "Luxturna", an innovative gene-based medicine for the treatment of blindness caused by inherited retinal disease.
The medicine's registration comes as part of MoHAP's innovative mechanism for its accelerators to evaluate and approve the world's breakthrough drugs in accordance with the 'Fast Track/Accelerate Process' system.
Al Olama, who is also the Vice Chairman of the Higher Committee for Drug Pricing and Registration, said that the the registration of Luxturna comes in line with the Ministerial Decree No. 28 of 2018 which outlines the mechanism for registering breakthrough and rare medicines.
"It's also part of the UAE's ongoing support for the global initiative, 'Vision 2020: The Right to Sight', launched by the World Health Organisation, WHO, to eliminate avoidable blindness by the year 2020," he added.
"We are witnessing a significant turning point with the expectation of experts that gene-based therapies will be expanded to include other incurable diseases. For that reason, the UAE has approved this new treatment as it paves the way towards future prospects for gene-based therapies which would help patients recover from a lot of complex diseases," Al Olama noted.
The approval of the UAE for this treatment is the third globally at a health authorities level. This comes in line with MoHAP's strategy to build quality and safety for therapeutic, healthcare and pharmaceutical systems according to international standards, as well as the UAE Vision 2021.
For his part, Dr. Mohamed Ezz El Din, Country Manager, Novartis, said, "We received some good news that MoHAP completed the registration process of Luxturna which is the first gene-based therapy in the UAE. We are looking forward to further strengthening our presence in the region to ensure that patients could get this global therapy that may change their lives.
"For those born with a mutation in both copies of the RPE65 gene, nearly 60 percent of patients have severe forms of the disease, with severe visual impairment occurring shortly after birth. RPE65 inherited retinal disease is a rare one, as mutations in both copies of the RPE65 gene affect approximately one in 200,000 people, however, mutations in both copies of the RPE65 gene can lead to blindness. Hence the importance of this innovative medicine, Luxturna, that restores sight and improves vision," added Dr. Ezz El Din.
71% of retail investors in the UAE hold stocks in companies engaged with AI
markets1 hour ago
This decision was taken to preserve the safety of administrative staff, teachers and students
uae2 hours ago
Abu Dhabi Police has been promoting the safety of motorcycle riders by holding workshops focused on improving traffic awareness
uae2 hours ago
The high-profile event brought together global philanthropic and business leaders to explore the untapped potential of philanthropic capital in accelerating development and humanitarian efforts
kt network2 hours ago
Many employees were told to report to office during the unprecedented rain and storm of April 16-17
uae2 hours ago
His more than 30 books are as likely to be found in airports as on university reading lists and have been translated into more than 40 languages
americas3 hours ago
The machine is a crucial asset during health crises like Covid-19
uae3 hours ago